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Deletions and reciprocal duplications of the chromosome 16p13.1 region have recently been
reported in several cases of autism and mental retardation (MR). As genomic copy number
variants found in these two disorders may also associate with schizophrenia, we examined
4345 schizophrenia patients and 35079 controls from 8 European populations for duplications
and deletions at the 16p13.1 locus, using microarray data. We found a threefold excess of
duplications and deletions in schizophrenia cases compared with controls, with duplications
present in 0.30% of cases versus 0.09% of controls (P=0.007) and deletions in 0.12 % of cases
and 0.04% of controls (P>0.05). The region can be divided into three intervals defined by
flanking low copy repeats. Duplications spanning intervals I and II showed the most significant
(P=0.00010) association with schizophrenia. The age of onset in duplication and deletion
carriers among cases ranged from 12 to 35 years, and the majority were males with a family
history of psychiatric disorders. In a single Icelandic family, a duplication spanning intervals I
and II was present in two cases of schizophrenia, and individual cases of alcoholism, attention
deficit hyperactivity disorder and dyslexia. Candidate genes in the region include NTAN1 and
NDE1. We conclude that duplications and perhaps also deletions of chromosome 16p13.1,
previously reported to be associated with autism and MR, also confer risk of schizophrenia.
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Introduction
Copy number variants (CNVs) are emerging as an
important genomic cause of autism, mental retarda-
tion (MR) and schizophrenia.1–8 There is no simple
pattern: several CNVs are associated with a broad
range of neuropsychiatric phenotypes with no respect
for traditional clinical diagnostic boundaries,4–6,8 and
no agreed explanation is found for this clinical and
genetic overlap.9–11 Despite high mutation rates,6
some recurrent CNVs seem to maintain themselves
at low frequencies in human populations through the
reduced fecundity and negative selection associated
with severe neuropsychiatric disorders such as aut-
ism, MR and schizophrenia.
Ullmann et al.12 performed a high-resolution, tiling
path BAC array comparative genomic hybridization
on DNA from 70 autistic individuals from an
Australian cohort. Identical submicroscopic 16p13.1
duplications were found in two unrelated patients.
The duplication encompassed an interval of 1.5Mb,
ranging from chromosome 16p, 14.89–16.39Mb
(Human Genome Build 35). A third duplication was
identified by quantitative PCR in a second Australian
cohort of 112 patients. Two of the duplications were
familial, and in one family, a severely autistic brother
of the index case also carried the duplication. One of
the brothers was continuously hyperactive, destruc-
tive and aggressive, whereas the younger brother was
passive and easy to manage. Other carriers included a
sister, who had learning difficulties and mother who
had learning difficulties coupled with obsessive–
compulsive disorder. They also reported two deletion
patients with severe MR. The former was de novo; the
latter had a mildly affected carrier mother. Hannes
et al.13 in a study of 1027 patients with MR and/or
multiple congenital anomalies found six deletions
and seven duplications in the chromosome 16p13
region. Five deletions and five duplications corre-
sponded roughly to the CNVs found by Ullmann
et al.12 with distal breakpoints at 14.7–14.75Mb and
proximal breakpoints at 16.3–16.77Mb (Human Gen-
ome Build 36). Two further duplications had distal
breakpoints at 15.1–15.4Mb and proximal break-
points at 18.05–18.45Mb, and one deletion had
breakpoints at 16.3–16.77 and 18.3–18.4Mb. Despite
phenotypic variability, common features included
three deletions with MR, microcephaly and epilepsy,
and three duplications with pronounced behavioral
problems in addition to MR and/or multiple con-
genital anomalies. However, when they examined the
region in roughly 2000 controls, they found five
duplications (no estimate of breakpoints provided)
and no deletions, leading them to the conclusion that,
although the deletion was probably pathogenic, the
reciprocal duplication might be benign.13
The chromosome 16p13.1 duplication/deletion
interval is located in a region with reported linkage
to bipolar disorder14–17 and to puerperal psychosis.18
In addition, analysis of 458 Finnish schizophrenia
families reported linkage to the DISC1 locus;19
however, when these families were later conditioned
for a risk haplotype spanning intron 1 and exon 2 of
the DISC1 gene, linkage was found in 16p13.1
region.20 The duplicated/deleted region contains the
gene coding the DISC1-binding protein, NDE1, and
the authors found significant allelic association
between NDE1 and schizophrenia. However, this
has not been confirmed in a recent Japanese study.21
Finally, another significant association was recently
reported between NDE1 and schizophrenia, when
schizophrenia cases and controls were conditioned
for the presence of Cys residue at the non-synon-
ymous polymorphism Ser704Cys encoded by the
DISC1 gene.22
In the present study, we assessed association of
CNVs in the 16p13.1 region with schizophrenia as
part of a genome-wide scan using the Illumina
microarrays HumanHap300, HumanHap550v3 and
Human 610-Quad (Illumina, San Diego, CA, USA);
and the Affymetrix SNP 6.0 microarray (Affymetrix,
Santa Clara, CA, USA) in a sample of 4345 schizo-
phrenia patients and 35 079 controls from 8 European
populations, namely, Iceland, Finland, Germany, the
Netherlands, Norway, Italy, Denmark and the United
Kingdom. Preliminary details on the Scottish sample
and part of the German sample have already been
documented.7,23
Materials and methods
Samples
A total of 4345 schizophrenia affected individuals
and 35 079 screened controls from eight European
populations were successfully examined at deCODE
for CNVs at the locus studied here; they comprised
1435 schizophrenia patients and 28554 control
individuals from Iceland, Scotland, Germany, Eng-
land, Italy and Finland (The SGENE sample; http://
www.SGENE.eu); to these were added a further 866
patients and 856 controls from Aberdeen, Scotland
and Munich, Germany; 491 patients and 881 controls
from Bonn, Germany; 502 patients and 477 controls
from Denmark; 806 Dutch cases and 4039 controls;
and 245 patients and 272 controls from Norway. For a
full description of samples see Supplementary
Information, part one. Ethical approval was obtained
from the local Ethics Committees. All participants
gave a written informed consent.
The SGENE samples were typed on the Human-
Hap300 BeadArray (Illumina) at deCODE genetics.
The additional samples from Aberdeen and Munich
were typed at Duke University in collaboration with
GlaxoSmithKline on HumanHap550v1 and Human-
Hap300 BeadArray (Illumina, respectively). The sam-
ples from Bonn were typed at Bonn University on the
HumanHap550v3 BeadArray (Illumina). The Dutch
samples from Utrecht University were genotyped at
the University of California, Los Angeles, on Human-
Hap550v3 BeadArray (Illumina). The remaining
Dutch samples were genotyped at deCODE genetics
on HumanHap300 BeadArray (Illumina). The Danish
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samples were genotyped at deCODE genetics on the
Human 610-Quad BeadArray (Illumina). The Norwe-
gian samples were genotyped on Affymetrix Gene-
Chip(r) GenomeWide SNP 6.0 array and analyzed
using the Affymetrix Power Tools 1.8.0.
CNV detection
Dosage Miner software developed at deCODE genetics
and QuantiSNP software developed at Wellcome
Trust Centre for Human Genetics and the University
of Oxford (http://www.well.ox.ac.uk/QuantiSNP/)24
were used to identify deletions and duplications
within the region reported by Ullmann et al. and
Hannes et al.12,13 Dosage Miner, described in detail
elsewhere,6 uses the intensities from single nucleo-
tide polymorphism (SNP) probes on the Illumina
microarrays to estimate copy number of genomic
regions and models factors, such as SNP effect,
sample effect and GC-content the in the neighboring
regions, to normalize the intensities. The software
then automatically registers SNP loci in which
intensities fall above or below an empirical threshold.
The QuantiSNP program relies on an Objective
Bayes Hidden-Markov Model to estimate copy num-
ber variations. In this model, the hidden states denote
the unknown copy number at the inspected SNPs.
Genotype data was used to compute different states.
The algorithm computes a Bayes factor that is used to
calibrate the model to a fixed type I (false-positive)
error rate. A Bayes factor threshold of 10 is considered
as a promising value for the possible presence
of a CNV. Usually, such values occur when 5–10
consecutive SNPs are deleted/duplicated. Differences
in GC base pairs may result in biased hybridization
behavior of SNP probes bearing the risk of miscalling
genotypes. To normalize this, QuantiSNP assigns a
locus-specific GC value to each probe. All potential
CNVs that were detected by both softwares, and
spanned at least 10 consecutive SNP probes, were
subsequently visually inspected and confirmed.
Association analysis
A two-tailed Cochrane–Mantel–Haentzel analysis
assuming common odds ratios was performed, strati-
fying samples by country of origin to take account of
the possible effect of geographical variation on the
results of the analysis.
Results
We limited our search on 16p13.1 to the region
between 14.66 and 18.70Mb (Human Genome
Build36). We subdivided the region into three single
copy sequence intervals, which we called intervals I,
II and III; each interval is flanked by sequences rich in
low copy repeats with 99% sequence homology
(Figure 1). The duplications and deletions previously
reported12,13 are all contained within this region, with
the most common breakpoints in the low copy repeat
clusters distal to interval I and proximal to interval II
(Figure 1).
Figure 1 The 16p13.11-p12.3 region. Chromosomal coordinates according to the Human Genome Build 36 are shown at top,
followed by genes from the Reference Sequence database. The locus is marked by regions of single copy sequence
interspersed with stretches of segmental duplications. The single copy regions, referred to in the article as I, II and III are
shown as black bars. Copy number variants (CNVs) identified by Ullmann et al.12 and Hannes et al.13 are also indicated with
black bars, gray bars reflect uncertainty of exact breakpoints. The genomic coverage of microarrays used in this study is also
shown, and reflects the division of the locus into single copy regions and segmental duplications, as does the coverage of
HapMap single nucleotide polymorphisms (SNPs) from the CEU trios and the track displaying segmental duplications. At
the bottom, we have depicted the largest low copy repeats in the region ( < 50kb) with high sequence homology ( > 98%),
different colors denote different repeats and arrows show directionality. Finally, we show the most likely sites for NaHR
causing four of the six CNVs found in the study.
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Table 1 lists the duplications and deletions found
in our sample, together with the population of origin.
None were found in cases or controls from England
(n=104 and 95), Italy (n=86 and 92), Finland (n=191
and 200) and Norway (n=245 and 272). Accordingly
these samples are not included in the table or in the
Cochran–Mantel–Haentzel statistical analysis.
Owing to varying geographical origin of the sam-
ples, we analyzed the data for association using
Cochran–Mantel–Haentzel algorithm to correct for
stratification. Within the total population examined,
we found a threefold excess of duplications and
deletions in cases compared with controls (see
Table 2). We found six distinct CNV categories in
the region, corresponding to deletions and reciprocal
duplications of three overlapping regions (Figure 2).
Duplications were present in 0.30% of schizophrenia
cases versus 0.09% controls (P=0.007). When analy-
sis was restricted to duplications containing intervals
I and II (Dup Iþ II, Figure 2), the significance
increased further (P=0.00010). The Dup Iþ II was
present in four male and two female Scottish cases,
two male Icelandic, one male Danish and three male
Dutch cases, as well as in 12 female and six male
Icelandic controls, in none of the Scottish controls
and in two Dutch male controls. Common odds ratio
was 8.79 (males) and 3.63 (females). The two
Icelandic cases were independently ascertained and
are included in the analysis as separate probands.
However, when genealogical analysis was later per-
formed, we found that the two were second-degree
relatives. Other carriers in the family included single
cases of alcoholism (under treatment), dyslexia
and attention deficit hyperactivity disorder (See
Supplementary Figure 1).
Deletions were present in 0.12% cases and 0.04%
controls (P>0.05). A deletion of interval I and II (Del
Iþ II, Figure 2) was present in 3 German and 1 Danish
schizophrenia cases, and 1 German and 10 Icelandic
controls (P>0.05), whereas a deletion of intervals II
and III (Del IIþ III, Figure 2) was present in 1 Scottish
schizophrenia case, and 2 German and 2 Icelandic
controls (P>0.05).
We also tested allelic association for all SNP
markers on the Illumina microarrays that spanned
the 16p13.1 region in 2687 schizophrenia cases and
13 484 controls. Although none of the markers in the
interval were genome-wide significant, one marker,
rs2283508, was associated (P=1.5E-05) and remained
significant after locus-wide correction P=0.0043 (117
markers tested). This marker is located within an
intron of the ABCC6 gene. No other markers spanning
the region were significant after correcting for the 117
markers on the HumanHap300 chip in the interval
spanning the duplication (see Supplementary Infor-
mation, part 3).
In view of the report22 of significant associations
between NDE1 and schizophrenia when schizophre-
nia cases were stratified by the presence of a Cys
residue at Ser704Cys of the DISC1 gene, we also
conditioned our schizophrenia cases. The DISC1
Ser704Cys SNP, rs821616, is not on the Human-
Hap300 chip. However, a SNP that is in complete
linkage disequilibrium (r2 = 1) with rs821616 in
Table 1 Duplications and deletions of 16p 13.1 in European populations
Icelanda Scotlandb Germany Hollandb Denmark
Status Scz Ctrl Scz Ctrl Scz Ctrl Scz Ctrl Scz Ctrl
No. of cases 648 27747 661 665 1102 1493 806 4039 502 477
Percentage of male 63 39 72 58 57 49 76 60 58 58
All Dup 2 24 6 1 1 0 3 6 1 1
All Del 0 12 1 0 3 3 0 0 1 0
Dup Iþ II 2 18 6 0 0 0 3 2 1 0
Dup II 0 3 0 1 0 0 0 1 0 1
Dup IIþ III 0 3 0 0 1 0 0 3 0 0
Del Iþ II 0 10 0 0 3 1 0 0 1 0
Del II 0 0 0 0 0 0 0 0 0 0
Del IIþ III 0 2 1 0 0 2 0 0 0 0
Abbreviations: ADHD, attention deficit hyperactivity disorder; CNV, copy number variant; Ctrl, control; Del, deletion;
Dup, duplication; Scz, schizophrenia.
aFurther duplications and deletions were detected in Icelandic samples that were excluded from the case–control analysis.
These include one autism case with Del II, one alcoholism case with Dup II, two alcoholism cases with Del Iþ II, one ADHD
and one alcoholism case with Dup IIþ III, and finally, four first-degree relatives of schizophrenia cases, two ADHD, two
alcoholism and one dyslexia case with Dup Iþ II (some of the Dup Iþ II carriers counted here are shown in figure 3).
bGenome-wide CNV results for 54 of the Dutch cases were published recently42 but these do not include carriers of CNVs at
16p13.1. The Scottish sample has been independently genotyped on the Affymetrix platform by the International
Schizophrenia consortium7, and 16p13.1 CNVs are listed with other CNV findings from that study at http://
pngu.mgh.harvard.edu/isc/isc-r1.cnv.bed. Furthermore, genome-wide CNV results for 866 patients and 856 controls of the
Scottish and German sample, including carriers of three of the Dup Iþ II as well as one of the Del Iþ II, the Del IIþ III and
Dup II found in this study, have been published elsewhere.43
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the Hapmap CEU population, rs821596, was present.
We therefore used rs821596 to divide the schizo-
phrenia cases into Cys704-carrier and non-carrier
groups, and then looked for allelic association with
SNPs at the NDE1 locus in the two groups. None were
significantly associated after correcting for the num-
ber of tested markers. The data regarding 51 SNPs in,
or within, 200Kb of NDE1 for the Cys704 carrier and
non-carrier groups are given in Supplementary
Information, part 3.
We also performed exploratory analyses. As the
majority of the duplication cases were Scottish in
origin, we examined the haplotype background of the
duplicated regions. The CNV occurred on a different
haplotype background in each individual. In addi-
tion, none of the non-Icelandic carriers, for whom we
had genotype data, had a CNV on the same haplotype
background as any of the Icelandic carriers. This
suggests that there was no founder mutation, and each
of the events is likely to have arisen independently.
Within Iceland itself, for each of the CNV duplication
and deletion subtypes (Figure 2) found in more than
one individual, there was no founder mutation. There
were also enough individuals in the Icelandic
population with Dup Iþ II to look at clustering
patterns. Clustering occurred at a rate of three- to
fourfold less than expected if the duplications were
selectively neutral. See Supplementary Information,
part 4 for discussion of cluster analysis.
Discussion
We have found a statistically significant (P=0. 007)
threefold overrepresentation of duplications in the
chromosome 16p13.1 region in schizophrenia cases
compared with controls. We found a similar threefold
overrepresentation of deletions in cases, but this was
not significant (P>0.05). The great majority of
duplications and deletions we found using Illumina
microarrays are identical to those reported by two
groups using array comparative genomic hybridiza-
tion.12,13 They span the same 1.5Mb region that
includes intervals that we refer to as intervals I and
II; we have also identified novel duplications and a
single deletion involving interval II only.
The distinction between CNVs involving intervals I
and II and interval II alone is dependent on a group of
seven SNP probes at 15.0–15.1Mb (Figure 1). How-
ever, we are confident that our classifications are
correct; every CNV detected by the independent
Dosage Miner and QuantiSNP algorithms was then
inspected by eye, and in all cases, we could make a
clear distinction between those involving both inter-
vals I and II (Dup/Del Iþ II) and interval II only
(Dup/Del II). In addition, genealogical analysis of the
Icelandic data set, performed post hoc, showed a clear
separation of CNV types. In total, 36 out of 54 carriers
were clustered in 11 families (ancestral clustering,
max depth three generations), including seven
families with Dup Iþ II (nine, three and five times
two carriers), two families with Del Iþ II (six and twoTa
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carriers), one family with Dup II (four carriers) and
one family with Dup IIþ III (two carriers). In no
instance did we observe two different CNVs segregat-
ing within the same family.
The breakpoints for all three types of deletion/
duplication are located in areas with high low copy
repeat content, reflecting apparent genomic instabil-
ity of the region.25 The repeats are in the same
orientation, and non-allelic homologous recombina-
tion (NaHR) between these low copy repeats seems to
be the most likely explanation for the recurrence of
the rearrangements and for their identical size. Three
inversion polymorphisms have previously been de-
scribed in the 16p13.1 region.26,27 A large duplication
in a patient with MR has also been reported,28 as has a
smaller de novo duplication.29 A much larger dupli-
cation (8Mb) of the region has also been reported in
two unrelated patients with autistic features.30
Our most striking finding is the increased risk of
schizophrenia associated with duplications at the
16p13.1 locus. Recurrent deletions at several loci
have now been reported to be significantly associated
with schizophrenia, but, to date, duplications asso-
ciated with schizophrenia have mostly been isolated
case reports. It is more difficult to decide whether the
duplications are genuinely pathogenic or benign. The
problem has already been encountered by Hannes
et al.13 with duplications in MR at this locus. They
found duplications in five out of 1027 cases, three of
whom had striking behavioral problems similar to
those reported by Ullmann et al.12 However, because
the duplication was present in 5 out of 2000 controls,
they could not decide whether it was genuinely
pathogenic. The different sizes of duplications and
deletions at the 16p13.1 locus also present difficulties
when it comes to assessing statistical association.
Statistically, we have used the straightforward
approach of counting all duplications and then
deletions as equivalent events, and only then tried
to condition on those duplications or deletions
that have the same breakpoints as those reported
previously in autism and MR/multiple congenital
anomalies.12,13
Although caution must be exercised when inter-
preting results from such a small number of cases,
there are several grounds supporting that our findings
are indeed genuine. First, given the rarity of the
duplications, the overall association with schizophre-
nia is statistically (P=0.0071) significant, and in-
creases (P=0.00010) when the Dup Iþ II is
considered separately. In addition, identical duplica-
tions at the 16p13.1 locus have already been found
Figure 2 Intensity plots for the Copy number variants (CNVs) identified in this study in the 16p13.11-p12.3 region.
Chromosomal coordinates according to the Human Genome Build 36 are shown at top, followed by markers from the
microarrays used in this study, HapMap single nucleotide polymorphisms (SNPs) from the CEU population and the track
displaying known segmental duplications. At the bottom, intensity plots from Dosage Miner are shown for one carrier of each
of the identified CNVs. The blue and green bars show the intervals of Dosage Miner automatic calls for deletions and
duplications, respectively.
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associated with autism.12 Second, four of the schizo-
phrenia duplication cases had an early onset of illness
(12, 17, 19 and 19 years) and in this respect resembled
the 16p13.1 deletion cases in which three of the five
schizophrenia cases also had early onset of illness
(15, 17 and 18 years, see Supplementary Information,
part 2). With a mean age at onset of 24 years, this
reflects an overrepresentation of early onset cases,
although not reaching significance. Third, in an
Icelandic family, the duplication co-segregates with
neuropsychiatric disorders, including two cases of
schizophrenia, and individual cases of attention
deficit hyperactivity disorder, dyslexia and alcohol-
ism. Owing to the small size of the family and the
diversity of the neuropsychiatric phenotypes, calcu-
lating a logarithm of the odds (LOD) score did not
seem appropriate. This range of phenotypes we
observe in a single family is not unexpected, as an
overlap of phenotypic features between autism and
attention deficit hyperactivity disorder has been
extensively reported, and individuals with attention
deficit hyperactivity disorder are at increased risk of
schizophrenia.31–33 Fourth, the duplications at this
locus seem to be under negative selection. Cluster
analysis of the Dup Iþ II events in the Icelandic
population finds that the carriers cluster less than
expected in families, that is, the genealogical clusters
are smaller, and sporadic carriers more numerous
than would be expected if the duplications were
selectively neutral. The arguments and methods are
laid out in Supplementary Information, part 4 and are
also given in Stefansson et al.6 These clustering
results, however, are informal, and so any conclu-
sions must be provisional. Fifth, Kirov et al.34 have
identified three chromosome 16p13.11 duplications
in 471 schizophrenia cases and 6 out of 2792 controls.
In addition, the International Schizophrenia Consor-
tium finds overrepresentation of large 16p13.11
duplications (13 of 3391 cases versus 7 of 3181
controls have duplications encompassing interval II,
see at http://pngu.mgh.harvard.edu/isc/isc-r1.cnv.
bed),7 but this overrepresentation is mostly explained
by the Aberdeen sample, which overlaps between our
study and the International Schizophrenia Consor-
tium study (although separately genotyped and
analyzed), and therefore, does not provide further
support to our finding.
Finally, with regard to the Dup Iþ II duplications,
although the Scottish sample seems to be driving the
association observed, as 6 out of 12 carriers among
affected cases belong to that sample, the association of
Dup Iþ II in this study remains significant even after
removing the Scottish samples from the analysis
(P=0.0033, OR=5.94).
The duplicated region contains two strong candi-
date genes (NTAN1 and NDE1), over- or underexpres-
sion of either or both of which at key stages of
neurodevelopment could predispose to autism, MR
and/or schizophrenia.
The NTAN1 gene is located in the small island of
non-repeated sequence called interval one. It encodes
an N-terminal asparagine amidase that has been
implicated in social behavior and memory. Over-
expression of NTAN1 leads to reduction in the
MAP2 (microtubule-associated protein 2) expression
through the ubiquitin proteasome pathway. Reduced
expression of MAP2 may be a useful marker for
diagnosis of schizophrenia and bipolar disorder
in vivo35,36 and in vitro.37,38 Mice with a disrupted
NTAN1 gene show less locomotion in an open field
and impairment of several spatial memory tasks.39,40
NDE1 and NDEL are highly homologous genes
involved in brain development, neuronal prolifera-
tion, migration and synapse formation. They encode
proteins that biologically interact with DISC1 and
LISI proteins, withNDE1 appearing to be interchange-
able with its homolog NDEL, except that NDE1 is
expressed earlier in development. nde1-null mice are
viable and display microcephaly with thinning
cortical layer and reduced numbers of neurons.
Interestingly, two out of three reported autism cases
with duplication had increased head circumference.12
The nde1-null mice display defects in neuronal
proliferation and neuronal migration. The NDE1
protein directly interacts with the DISC1 protein at
the C-terminal end that is distal to a truncating
mutation that is reported to segregate with schizo-
phrenia and other forms of major mental illness in a
large Scottish DISC1 translocation family.41,42 As
truncated DISC1 is known to alter NDE1/NDEL
function, the duplications we report here may have
a similar biological effect as the truncating mutation
associated with schizophrenia in the Scottish family.
All duplications and deletions in our study involve
interval II that harbors the NDE1 gene and this makes
dysregulation of NDE1 expression the most parsimo-
nious explanation for the increased risk of the
phenotypes reported by Ullmann et al.12 and by the
authors of this paper. On the other hand, the strongest
association is with duplications that also involve
interval I. It is possible that combined changes in
expression of NTAN1 and NDE1 increase suscept-
ibility over changes in expression of NDE1 alone. No
clear-cut findings emerged from our examination of
the 16p13.1 region for allelic association for schizo-
phrenia. The findings are discussed along with
association studies following conditioning for DISC1
Ser704Cys in Supplementary Information, part 3.
Further work is required before the clinical im-
plications of our findings become clear. On the one
hand, the data strongly suggest that recurrent dupli-
cations at 16p13.1 locus increase the risk of schizo-
phrenia. They also strengthen the hypothesis that
there are shared genetic risk factors between schizo-
phrenia, MR and autism. However, the odds ratios,
even for the Dup Iþ II, are substantially less than the
increased risks we have observed for three out of four
recurrent deletions on chromosomes 1, 15 and 22.6
Whether the smaller odds ratio we observe for
duplications is a feature of the 16p13.1 locus itself,
or it is part of a broader rule that recurrent duplica-
tions are generally less penetrant than recurrent
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deletions, remains to be determined. The 16p13.1
duplications we observe are rare, at a rate of about 3 or
4 per 1000 schizophrenia cases, and, estimating from
the control population in the present study, about
0.08% in the general population. This makes it
difficult to obtain precise measurements of overall
risk or risk for individual neuropsychiatric disorders.
Analysis of CNV data from sets of cases and controls
considerably larger than the sets we report in this
paper, which itself to date is one of the largest
assembled, will be required. These and many other
questions will need to be answered before the exciting
findings that arise from CNV analysis can be used in
clinical practice for diagnostics, disease classification
or genetic testing.
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